14-3-3 IMPLICATIONS IN TOPOISOMERASE II PHARMACOLOGY
14-3-3 IMPLICATIONS IN TOPOISOMERASE II PHARMACOLOGY
批准号:
2448928
负责人:
David J Kroll
金额:
$16.84万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-01-01 至 1999-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme
which catalyzes the interconversion of the various tertiary structures of
DNA. This enzyme is absolutely essential to cellular proliferation since it
decatenates physically interlocked DNA prior to mitosis. Topo II is also a
clinically relevant target for a widely useful class of chemotherapeutic
drugs. The study of topo II biochemistry has revealed several mechanisms by
which tumor cells respond to, or evade, the cytotoxic effects of the
topo-II-directed anticancer drugs. In the past three years, the Principal
Investigator has been developing the hypothesis that topo II activity can be
mediated by protein-protein interactions and modulation of these proteins
may also affect tumor cell response to topo II poisons. Others have
described topo II interactive proteins (TIPs) from yeast and Drosophila that
are necessary for faithful chromosomal segregation. A human homolog of the
yeast TIP, Sgs1, is likely to be the causative gene that is altered in
Bloom's syndrome. Therefore, study of topo II protein interactions has
revealed unappreciated roles for the enzyme in human neoplasia.
The Principal Investigator's studies propose to focus instead on the role of
topo II protein interactions in the cytotoxic action of topo-II-directed
drugs. Toward this aim, a human HeLa cell cDNA expression library has been
screened for proteins that interact with the C-terminus of the major alpha
form of human topo II. One of the TIPs has been identified as the epsilon
isoform of human 14-3-3 protein. 14-3-3 proteins, an unusually highly
conserved protein family found in plants, fungi, and mammals, have been
implicated repeatedly in numerous protooncogenic and oncogenic cellular
signaling pathways. 14-3-3 proteins also appear to sequester the apoptotic
death agonist, Bad, in IL-3 protection of T cells. The Principal
Investigator therefore proposes 1) to test whether the 14-3-3/topo II
interaction is authentic and occurs in intact cells and 2) to investigate
the biochemical and pharmacological consequences of this interaction in
tumor cells overexpressing 14-3-3 protein. The high level of conservation
of 14-3-3 proteins, their implication in cellular growth signaling and now
apoptosis, suggest that 14-3-3/topo II interactions are likely to be
biologically significant. Most importantly, these interactions may also
modulate tumor cell susceptibility to topo-II-directed antitumor drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NORTH CAROLINA CENTRAL UNIVERSITY EAGLES RISE WITH MENTORING THROUGH THE DOCTORAL
-
批准号:7936705
-
项目类别:
-
资助金额:$23.21万
-
财政年份:2010
-
负责人:David J Kroll
-
依托单位:
Formulation Dependent Help Interactions with Chemothera*
-
批准号:6874544
-
项目类别:
-
资助金额:$28.11万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
Formulation Dependent Help Interactions with Chemothera*
-
批准号:6769285
-
项目类别:
-
资助金额:$27.75万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
Pure Flavonolignans from S. marianum in Prostate Cancer
-
批准号:7022926
-
项目类别:
-
资助金额:$38.39万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
Pure Flavonolignans from S. marianum in Prostate Cancer
-
批准号:7226316
-
项目类别:
-
资助金额:$38.33万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
Pure Flavonolignans from S. marianum in Prostate Cancer
-
批准号:6707179
-
项目类别:
-
资助金额:$36.64万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
Pure Flavonolignans from S. marianum in Prostate Cancer
-
批准号:6882683
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2004
-
负责人:David J Kroll
-
依托单位:
14 3 3 Implications in Topoisomerase II Pharmacology
-
批准号:6556228
-
项目类别:
-
资助金额:$14.05万
-
财政年份:1998
-
负责人:David J Kroll
-
依托单位:
14 3 3 Implications in Topoisomerase II Pharmacology
-
批准号:6603947
-
项目类别:
-
资助金额:$32.57万
-
财政年份:1998
-
负责人:David J Kroll
-
依托单位:
14-3-3 IMPLICATIONS IN TOPOISOMERASE II PHARMACOLOGY
-
批准号:2856477
-
项目类别:
-
资助金额:$16.69万
-
财政年份:1998
-
负责人:David J Kroll
-
依托单位:
14 3 3 Implications in Topoisomerase II Pharmacology
-
批准号:6333237
-
项目类别:
-
资助金额:$12.57万
-
财政年份:1998
-
负责人:David J Kroll
-
依托单位:
14 3 3 Implications in Topoisomerase II Pharmacology
-
批准号:6513145
-
项目类别:
-
资助金额:$32.57万
-
财政年份:1998
-
负责人:David J Kroll
-
依托单位:
DNA TOPOISOMERASE II PROTEIN/PROTEIN INTERACTIONS
-
批准号:2188186
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1994
-
负责人:David J Kroll
-
依托单位:
ASSOCIATION OF DNA TOPOISOMERASE II WITH CREB
-
批准号:2135740
-
项目类别:
-
资助金额:$2.99万
-
财政年份:1993
-
负责人:David J Kroll
-
依托单位:
ASSOCIATION OF DNA TOPOISOMERASE II WITH CREB
-
批准号:2135741
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1993
-
负责人:David J Kroll
-
依托单位:
海外基金